SC Established cytotoxic chemotherapy 5 mcg/kg/day. 1st dose should be administered at least 24 hr after cytotoxic chemotherapy.
Patient treated w/ myeloablative therapy followed by bone marrow transplantation 10 mcg/kg/day. 1st dose should be administered at least 24 hr following cytotoxic chemotherapy & at least 24 hr after bone marrow infusion.
Mobilisation of PBPCs in patient undergoing myelosuppressive or myeloablative therapy followed by autologous PBPC transplantation 10 mcg/kg/day for 5-7 consecutive days. Timing of leukapheresis: 1 or 2 on days 5 & 6. Maintain dosing until the last leukapheresis.
PBPC mobilisation after myelosuppressive chemotherapy 5 mcg/kg/day from the 1st day after completion of chemotherapy until the expected neutrophil nadir is passed & neutrophil count has recovered to normal range.
Mobilisation of PBPCs in normal donors prior to allogeneic PBPC transplantation 10 mcg/kg/day for 4-5 consecutive days. Start leukapheresis at day 5 & continued until day 6 if needed.
Congenital neutropenia Starting dose: 12 mcg/kg/day as single dose or divided doses.
Idiopathic or cyclic neutropenia Starting dose: 5 mcg/kg/day as single dose or divided doses.
Reversal of neutropenia in patient w/ HIV infection Starting dose: 1 mcg/kg/day w/ titration up to max of 4 mcg/kg/day until a normal neutrophil count is reached & can be maintained.
Maintenance of normal neutrophil counts Initial dose adjustment to alternate day dosing: 300 mcg/day.
Sign Out
